Hokkaido Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net July 5, 2025
Japan News Nadofaragene Firadenovec Shows Promise in Japanese Patients With BCG-Unresponsive NMIBC April 22, 2025
